Skip to main content
Premium Trial:

Request an Annual Quote

BioMarker Strategies Gets $1.7M in Private Investment

NEW YORK (GenomeWeb News) – BioMarker Strategies has raised $1.7 million through a private funding round that included the Abell Foundation, the Baltimore-based company said today.

BioMarker Strategies is developing a tumor biopsy processing and testing system called SnapPath that is intended to quickly analyze a solid sample at the point of biopsy. It also is developing a series of pathway-based, ex-vivo biomarker tests to help physicians make therapeutic decisions for cancer patients.

The investment came in conjunction with the Maryland Biotechnology Investment Incentive Tax Credit Program. The firm is situated at the Johns Hopkins Science and Technology Park, located in East Baltimore.

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.